Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Emergent BioSolutions (EBS) PT Raised to $130 at Cantor Fitzgerald Following EPS
February 19, 2021 7:39 AM ESTCantor Fitzgerald analyst Brandon Folkes raised the price target on Emergent BioSolutions (NYSE: EBS) to $130.00 (from $110.00) while maintaining an Overweight rating.
The analyst commented, "Post 4Q20, we reiterate our Overweight rating and raise our 12-month price target to $130, from $110. EBS continues to be... More
Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus
February 18, 2021 4:20 PM ESTEmergent BioSolutions (NYSE: EBS) reported Q4 EPS of $3.67, $0.48 better than the analyst estimate of $3.19. Revenue for the quarter came in at $583 million versus the consensus estimate of $563.94 million.
Emergents financial and operational performance in 2020 reflects the impact we are making in addressing the... More
